Akèy › Twoub depresif majè › Maryland
Etid klinik pou Twoub depresif majè nan Maryland
20 etid pou Twoub depresif majè ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Characterization and Treatment of Adolescent Depression
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 11 a 25 · Tout sèks · Mizajou Sep 28, 2026 · NCT03388606A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Delricht Research - Rockville, Rockville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07621237A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Johns Hopkins University, Baltimore
Ap rekriteFaz 3
Laj 12 a 17 · Tout sèks · Mizajou Sep 25, 2026 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Sunstone Medical, PC, Rockville
Ap rekriteFaz 3
Laj 18 a 85 · Tout sèks · Mizajou Sep 25, 2026 · NCT06793397Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 22, 2026 · NCT03065335Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- National Institutes of Health Clinical Center, Bethesda
- University of Maryland, College Park, College Park
Ap rekriteFaz 2Volontè an sante akeyi
Laj 8 a 65 · Tout sèks · Mizajou Sep 22, 2026 · NCT00018057Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Sep 14, 2026 · NCT06511908Defining Neurobiological Links Between Substance Use and Mental Illness
- National Institute on Drug Abuse, Baltimore
Ap rekriteVolontè an sante akeyi
Laj 18 a 60 · Tout sèks · Mizajou Sep 11, 2026 · NCT05538910Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 10, 2026 · NCT03973268Neurobiology of Suicide
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT02543983A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Pharmasite Research Inc., Baltimore
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 8, 2026 · NCT07076407A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Pharmasite Research, Inc., Baltimore
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Aug 28, 2026 · NCT07573176A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Gaithersburg
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Aug 26, 2026 · NCT07300969Natural History of Depression, Bipolar Disorder and Suicide Risk
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Aug 14, 2026 · NCT06462196NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 8 a 70 · Tout sèks · Mizajou Aug 13, 2026 · NCT05669703A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Pharmasite Research, Inc., Baltimore
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Aug 6, 2026 · NCT07412756A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Continental Clinical Solutions, Towson
Ap rekriteFaz 2
Laj 18 a 64 · Tout sèks · Mizajou Jul 27, 2026 · NCT07115329Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Gaithersburg
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT06966401Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Pikesville
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jul 24, 2026 · NCT07484217A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Sheppard Pratt, Baltimore
- Sunstone Medical, PC, Rockville
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou May 11, 2026 · NCT06524830Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.